0 analysts offer recommendations for CRISPR Therapeutics AG (CRSP) stock

The price of CRISPR Therapeutics AG (NASDAQ: CRSP) closed at $65.88 in the last session, down -1.96% from day before closing price of $67.20. In other words, the price has decreased by -$1.32 from its previous closing price. On the day, 1184001 shares were traded. CRSP stock price reached its highest trading level at $66.74 during the session, while it also had its lowest trading level at $64.30.

Unlock the Hottest Top 10 Penny Stocks Today! Discover Now

Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.

Gain Access to Top 10 Penny Stocks Now!.



We take a closer look at CRSP’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 13.00 and its Current Ratio is at 13.00. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.

Upgrades & Downgrades

Insider Transactions:

An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Apr 25 when Kulkarni Samarth sold 25,000 shares for $50.67 per share. The transaction valued at 1,266,638 led to the insider holds 387,377 shares of the business.

Kulkarni Samarth sold 25,000 shares of CRSP for $1,111,504 on Mar 29. The Chief Executive Officer now owns 387,377 shares after completing the transaction at $44.46 per share. On Feb 27, another insider, Kulkarni Samarth, who serves as the Chief Executive Officer of the company, sold 25,000 shares for $48.25 each. As a result, the insider received 1,206,243 and left with 375,988 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRSP now has a Market Capitalization of 5.35B and an Enterprise Value of 3.78B. For the stock, the TTM Price-to-Sale (P/S) ratio is 52.95 while its Price-to-Book (P/B) ratio in mrq is 2.79. Its current Enterprise Value per Revenue stands at 37.65 whereas that against EBITDA is -7.01.

Stock Price History:

Over the past 52 weeks, CRSP has reached a high of $86.95, while it has fallen to a 52-week low of $38.94. The 50-Day Moving Average of the stock is 51.80, while the 200-Day Moving Average is calculated to be 54.94.

Shares Statistics:

According to the various share statistics, CRSP traded on average about 1.29M shares per day over the past 3-months and 1.5M shares per day over the past 10 days. A total of 78.68M shares are outstanding, with a floating share count of 77.23M. Insiders hold about 0.50% of the company’s shares, while institutions hold 69.00% stake in the company. Shares short for CRSP as of May 14, 2023 were 12.43M with a Short Ratio of 13.20M, compared to 12.95M on Apr 13, 2023. Therefore, it implies a Short% of Shares Outstanding of 15.75% and a Short% of Float of 15.96%.

Earnings Estimates

The company has 21 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$2.12 for the current quarter, with a high estimate of -$1.56 and a low estimate of -$2.32, while EPS last year was -$2.4. The consensus estimate for the next quarter is -$2.03, with high estimates of $0.31 and low estimates of -$2.71.

Analysts are recommending an EPS of between -$3.17 and -$8.17 for the fiscal current year, implying an average EPS of -$6.18. EPS for the following year is -$6.46, with 24 analysts recommending between $1.55 and -$12.73.

Revenue Estimates

Based on 23 analysts’ estimates, the company’s revenue will be $264.82M in the next fiscal year. The high estimate is $2.23B and the low estimate is $4M. The average revenue growth estimate for next year is up 29.50% from the average revenue estimate for this year.